Printer Friendly

United Therapeutics Corporation's NDA for oral treprostinil for pulmonary arterial hypertension under FDA review.

M2 EQUITYBITES-February 22, 2012-United Therapeutics Corporation's NDA for oral treprostinil for pulmonary arterial hypertension under FDA review(C)2012 M2 COMMUNICATIONS http://www.m2.com

Biotechnology company United Therapeutics Corporation (NASDAQ:UTHR) stated on Tuesday that its new drug application (NDA) for treprostinil diethanolamine sustained release tablets for the treatment of pulmonary arterial hypertension is now under review.

This new drug application (NDA) for treprostinil diethanolamine sustained release tablets (oral treprostinil) has been accepted for review by the the US Food and Drug Administration, added the company.

The company said the NDA will be subjected to a standard ten month review period, with a targeted user fee deadline of 27 October 2012.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Feb 22, 2012
Words:123
Previous Article:-Rentenbank upsizes 2018 bond by NOK150m.
Next Article:Publicis Groupe acquires U-Link Business Solutions in China.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters